TrialSignal
Clinical trial intelligence report
A Phase 1b/2 Study to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT07369076-Jul 28, 2026
NCT ID
NCT07369076
Status
RECRUITING
Phase
PHASE1
Sponsor
Nura Bio
Executive brief
Investment-Ready Snapshot
A Phase 1b/2 Study to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis. is a PHASE1 clinical asset sponsored by Nura Bio in Amyotrophic Lateral Sclerosis (ALS). SEO and diligence focus: NB-4746 High dose, NB-4746 Low dose, Placebo, NB-4746 (Dose TBD), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT07369076
Indication
Amyotrophic Lateral Sclerosis (ALS)
Modality
small molecule
Target
NB-4746 High dose, NB-4746 Low dose, Placebo, NB-4746 (Dose TBD)
Intervention
NB-4746 High dose, NB-4746 Low dose, Placebo, NB-4746 (Dose TBD)
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.